Previous 10 | Next 10 |
Gainers: BREW +122.2% . KDMN +18.1% . ICUI +11.1% . APYX +6.8% . GO +6.6% . More news on: Craft Brew Alliance, Inc., Kadmon Holdings, Inc., ICU Medical, Inc., Stocks on the move, Read more ...
Reata Pharmaceuticals (NASDAQ: RETA ) announces positive results from the Phase 3 part of its Phase 2/3 clinical trial, CARDINAL , evaluating bardoxolone methyl in patients with chronic kidney disease (CKD) caused by a rare inherited disorder called Alport syndrome . More news on: Reat...
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT ACHIEVED KEY SECONDARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN RETAINED EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT AND WITHDRAWAL OF DRU...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
IRVING, Texas, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on November 12, 2019, before th...
Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...
Attention on Reata ( RETA ) has grown over the last two weeks, as the stock has surged by over 130% in light of strong pivotal phase 2 results for omaveloxolone as well as Reata's reacquisition of rights from AbbVie (ABBV). In this note, I'll first detail the reacquisition of the rights as w...
While earnings season is under way, investors in biotech stocks must also stay abreast of the latest data emerging from major medical meetings. At these events, biotech and pharmaceutical companies vie for top billing to showcase the latest results on clinical trials and new drug candidates. ...
It's been a busy October for Reata Pharmaceuticals (NASDAQ: RETA) , which kicked things off Oct. 10 with the announcement that it would end its nine-year partnership with AbbVie (NYSE: ABBV) . This move allows Reata to reclaim the exclusive rights to two drugs in late-stage clinical trials...
The stock market jumped higher on Tuesday, buoyed by a couple of favorable trends. Earnings season got off to a positive start, with several high-profile companies giving optimistic assessments of the current state of the U.S. economy. Also, comments from the European Union raised hopes that a U...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023